Immune Design Corp (NASDAQ:IMDZ) EVP Stephen R. Brady sold 3,328 shares of the stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $4.17, for a total value of $13,877.76. Following the transaction, the executive vice president now directly owns 50,490 shares of the company’s stock, valued at $210,543.30. The sale was disclosed in a filing with the SEC, which is available at this link.

Immune Design Corp (NASDAQ:IMDZ) traded down $0.28 during midday trading on Monday, reaching $3.93. The company had a trading volume of 476,690 shares, compared to its average volume of 630,919. Immune Design Corp has a 12-month low of $3.50 and a 12-month high of $13.05. The stock has a market cap of $188.63, a P/E ratio of -1.84 and a beta of 2.36.

Immune Design (NASDAQ:IMDZ) last released its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.11. Immune Design had a negative return on equity of 68.69% and a negative net margin of 619.62%. The firm had revenue of $0.52 million during the quarter, compared to the consensus estimate of $0.62 million. equities research analysts forecast that Immune Design Corp will post -1.89 EPS for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IMDZ. State of Wisconsin Investment Board purchased a new position in Immune Design in the 2nd quarter valued at approximately $117,000. Alliancebernstein L.P. purchased a new position in Immune Design in the 2nd quarter valued at approximately $118,000. Virtu KCG Holdings LLC purchased a new position in Immune Design in the 2nd quarter valued at approximately $153,000. Dimensional Fund Advisors LP increased its stake in Immune Design by 9.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 18,896 shares of the biotechnology company’s stock valued at $184,000 after purchasing an additional 1,600 shares in the last quarter. Finally, Rhumbline Advisers increased its stake in Immune Design by 53.9% in the 2nd quarter. Rhumbline Advisers now owns 19,694 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 6,896 shares in the last quarter. 29.34% of the stock is owned by hedge funds and other institutional investors.

IMDZ has been the subject of a number of analyst reports. Cowen reissued a “buy” rating on shares of Immune Design in a research note on Monday, December 11th. Wells Fargo & Co downgraded Immune Design from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $29.00 to $10.00 in a research note on Tuesday, October 17th. ValuEngine downgraded Immune Design from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 21st. Zacks Investment Research downgraded Immune Design from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. Finally, Royal Bank of Canada initiated coverage on Immune Design in a research note on Thursday, September 14th. They set an “outperform” rating and a $20.00 target price for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $13.06.

TRADEMARK VIOLATION WARNING: “Stephen R. Brady Sells 3,328 Shares of Immune Design Corp (IMDZ) Stock” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.watchlistnews.com/stephen-r-brady-sells-3328-shares-of-immune-design-corp-imdz-stock/1799091.html.

Immune Design Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Insider Buying and Selling by Quarter for Immune Design (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with Analyst Ratings Network's FREE daily email newsletter.